Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | JAK1 | P23458 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24579076 | 1.00 | CHRM1 (0.40) | CHRM1PDGFRAHRH3NTRK1JAK2 | |
| SCHEMBL24579030 | 0.92 | CHRM1 (0.41) | CHRM1PDGFRAHRH3NTRK1JAK2 | |
| SCHEMBL30809509 | 0.90 | PDGFRA (0.42) | CHRM1PDGFRAHRH3NTRK1JAK2 | |
| SCHEMBL30809534 | 0.86 | PDGFRA (0.56) | CHRM1PDGFRAHRH3 | |
| SCHEMBL29760114 | 0.85 | CHRM1 (0.42) | CHRM1PDGFRAHRH3NTRK1JAK2 | |
| SCHEMBL24577729 | 0.85 | CHRM1 (0.42) | CHRM1PDGFRAHRH3NTRK1JAK2 | |
| SCHEMBL24577317 | 0.85 | PDGFRA (0.41) | CHRM1PDGFRAHRH3 | |
| SCHEMBL29759553 | 0.84 | ALDH1A1 (0.38) | JAK2JAK1ALDH1A1 | |
| SCHEMBL27185059 | 0.84 | ALDH1A1 (0.38) | JAK2JAK1ALDH1A1 | |
| SCHEMBL24577404 | 0.83 | PDGFRA (0.45) | CHRM1PDGFRAHRH3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | CHRM1 4399/4885PDGFRA 1/4885HRH3 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.